Novel inhibitors of the hepatitis C virus NS3 proteinase

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 19, 2005, Pages 4275-4278

  Bennett, Frank ^a   Liu, Yi Tsung ^a   Saksena, Anil K ^a   Arasappan, Ashok ^a   Butkiewicz, Nancy ^a   Dasmahapatra, Bimalendu ^a   Pichardo, John S ^a   Njoroge, F George ^a   Patel, Naginbhai M ^a   Huang, Yuhua ^a   Yang, Xiaozheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Hepatitis; Proteinase

Indexed keywords

4 METHYL 1 (PHENYLMETHYL) 2,6 PYRIDINEDIONE; DIMER; PROTEINASE INHIBITOR; SILICA GEL; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; AUTOOXIDATION; DRUG SYNTHESIS; HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; DIMERIZATION; HEPATITIS C; INHIBITORY CONCENTRATION 50; OXIDATION-REDUCTION; PYRIDINES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 23944459090     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.06.079     Document Type: Article

References (26)

1. Q.-L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Science 244 1989 359
2. G. Kuo, Q.-L. Choo, H.J. Alter, G.L. Gitnik, A.G. Redeker, R.H. Purcell, T. Miyamuza, J.L. Dienstag, M.J. Alter, C.E. Stevens, G.E. Tegtmeier, F. Bonino, M. Colombo, W.-S. Lee, C. Kuo, K. Berger, J.R. Shuster, L.R. Overby, D.W. Bradley, and M. Houghton Science 244 1989 362
3. M.J. Alter, S.C. Hadler, F.N. Judson, A. Mares, W.J. Alexander, P.J. Hu, J.K. Miller, L.A. Moyer, H.A. Fields, D.W. Bradley, and H.S.J. Margolis J. Am. Med. Assoc. 264 1990 2231
4. K. Shimotohno Semin. Virol. 4 1993 305
5. D. Bresters Hepatitis C Treatment H.W. Reesink Hepatitis C Virus 1994 Karger Basel 121
6. M. Houghton Hepatitis C Virus 3rd ed. B.N. Fields D.M. Knipe D.M. Howley Virology Vol. 1 1995 Raven Press New York 1035 1058
7. C.M. Rice Flaviviridae: The Viruses and Their Replication 3rd ed. B.N. Fields D.M. Knipe D.M. Howley Virology Vol. 1 1995 Raven Press New York 931 960
8. R. Bartenschlager, L. Ahlborn-Laake, J. Mous, and H. Jacobsen J. Virol. 67 1993 3835
9. C. Lin, and C.M. Rice Proc. Natl. Acad. Sci. U.S.A. 92 1995 7622
10. 35S- labeled translated substrate in a 20 μl volume containing 10 mM Tris, pH 7.5, 120 mM NaCl, 5 mM DTT, 0.5% EDTA, 0.1% Tween 20, and 12% glycerol followed by incubation at 30°C for 30 min. Inhibitors were added to assay mixtures prior to incubation. In-house standards of HCV protease inhibitor molecules served as positive controls. Cleavage reactions were terminated by addition of an equal volume of 2x Laemmli sample buffer and boiling for 3 min. Cleavage products were analyzed by SDS/15% PAGE gel electrophoresis and autoradiography.
11. R.E. Babine, and S.L. Bender Chem. Rev. 97 1997 1359
12. M. Chu, R. Mierzwa, I. Truumees, A. King, M. Patel, R. Berrie, A. Hart, N. Butkiewicz, B. DasMahapatra, T.-M. Chan, and M.S. Puar Tetrahedron Lett. 37 1996 7229
13. W. Han, Z. Hu, X. Jiang, and C.P. Decicco Bioorg. Med. Chem. Lett. 10 2000 711
14. F. Narjes, M. Brunetti, S. Colarusso, B. Gerlach, U. Koch, G. Bisasiol, D. Fattori, R. DeFrancesco, V.G. Matassa, and C. Steinkuhler Biochemistry 39 2000 1849
15. J.M. Bennett, A.D. Campbell, A.J. Campbell, M.G. Carr, R.M. Dunsdon, J.R. Greening, D.N. Hurst, N.S. Jennings, P.S. Jones, S. Jordan, P.B. Kay, M.A. O'Brien, J. King-Underwood, T.M. Raynham, C.S. Wilkinson, T.C. Wilkinson, and F.X. Wilson Bioorg. Med. Chem. Lett. 11 2001 355
16. D.M. Andrews, H. Chaignot, B.A. Coomber, A.C. Good, M.R. Hind Johnson, P.S. Jones, G. Mills, J.E. Robinson, T. Skarzynski, M.J. Slater, and D. O'NSomers Org. Lett. 4 2002 4479
17. W. Han, Z. Hu, X. Jiang, Z.R. Wasserman, and C.P. Decicco Bioorg. Med. Chem. Lett. 13 2003 1111
18. Perni, R. B.; Chandorkar, G.; Chen, S. H.; Colacino, J.; Chaturvedi, P.; Courtney, L. F.; Decker, C.; Gates, C.; Harbeson, S. L.; Kwong, A. D.; Lin, C.; Lin, K.; Monroe, J. E.; Luong, Y.-P.; Murko, M. A.; Pitlik, J.; Rao, G.; Tebbe, M.; Tung, R. D.; Thomson, J. A. VX-950: The Discovery of an Inhibitor of the Hepatitis C NS3-4A Protease and a Potential HCV Therapeutic. AASLD Annual Meeting, Boston, MA, October 24-28, 2003.
19. M. Llinas-Brunet, M.D. Bailey, G. Bolger, C. Brochu, A.-M. Faucher, J.M. Ferland, M. Garneau, E. Ghiro, V. Gorys, C. Grand-Maitre, T. Halmos, N. Lapeyre-Paquette, F. Liard, M. Poirer, M. Rheaume, Y.S. Tsantizos, and D. Lamarre J. Med. Chem. 47 2004 1605
20. S.H. Chen, J. Lamar, Y. Yip, F. Victor, R.B. Johnson, Q.M. Wang, J.I. Glass, B. Heinz, J. Colacino, D. Guo, M. Tebbe, and J.E. Munroe Letters Drug Des. Discov. 2 2005 118
21. 6 requires 457.1400.
22. D. Nasipuri, G. Das, and I.D. Dalal J. Chem. Soc., Perkin Trans. 1 1977 2558
23. V. Karnojitzky Russ. Chem. Rev. (Engl. Transl.) 50 1981 888
24. 2 and in-house standards of HCV protease inhibitor molecules served as positive controls. After stopping the reaction, cleavage of the Cys-Ser bond was detected by the addition of streptavidin-coated SPA beads (Amersham), which can bind to the biotin-labeled peptide. Cleavage is indicated by reduction in signal caused by separation of the radiolabeled fragment from the bound biotinylated fragment (measured in CPM) which is proportional to proteolytic activity.
25. 3 requires 230.0817.
26. R. Zhang, B.M. Beyer, J. Durkin, R. Ingram, F.G. Njoroge, W.T. Windsor, and B.A. Malcolm Anal. Biochem. 270 1999 268